WuXi STA breaks ground for new pharmaceutical manufacturing facility in Middletown, Delaware

Published: 17-Aug-2022

WuXi STA, a leading contract research, development and manufacturing organisation (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware

First announced in June 2021, this site will be WuXi STA’s second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the US and around the world.

The WuXi STA Middletown site is located in the Middletown Business Center at 1091 Industrial Drive, and the new state-of-the-art facility will create approximately 500 full-time jobs by 2026.

Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.

WuXi STA has 12 sites across the U.S., Europe and Asia that offer a range of services and meet or exceed all regulatory standards. Together with three other drug product manufacturing sites in Couvet (Switzerland), Wuxi City (China) and Shanghai (China), this new facility will further enhance the company’s global drug production capacity and capabilities.

“The biopharmaceutical industry is part of Delaware’s DNA,” said Delaware Governor John Carney.

“During the next 5 years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware’s fastest-growing communities, bringing with it good jobs and economic growth. This campus is only possible because of Delaware’s world-class, innovative workforce. Thank you to WuXi STA, Middletown Mayor Kenny Branner and everyone who made this project possible.”

“The First State continues to be a first-rate destination for businesses looking to innovate and grow,” said Senator Tom Carper. “This investment by WuXi STA helps position Delaware as a continued global leader in biopharmaceuticals, further cementing the manufacturing might of one of our fastest growing communities."

"Delaware’s workforce is ready to help build the future of our life-saving pharmaceuticals. This state-of-the-art campus will create good jobs and help fortify our supply chains here at home.”

“This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region,” said Senator Chris Coons.

“I am excited about WuXi STA’s decision to choose Middletown for one of their new manufacturing facilities. This isn’t just the largest private-sector investment in Middletown’s history – it’s a defining moment that will bring many more good-paying jobs to Delaware and will further cement the First State as a world leader in biopharmaceutical research and manufacturing."

"I would like to thank our federal, state and local partners in Delaware for their continued support in the establishment of this site,” said Dr Minzhang Chen, coCEO of WuXi AppTec and CEO of WuXi STA.

“WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated CRDMO platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.”

Trending Articles

You may also like